Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats

Brain Research

Volumn 1276, Issue , 2009, Pages 171-179

  Song, Lu ^a   Kong, Min ^a   Ma, Yaping ^a   Ba, Maowen ^b   Liu, Zhenguo ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Department of Neurology   (China)

Author keywords

8 (3 chlorostryryl) caffeine (CSC); Adenosine A2A receptor; Motor complications; Parkinson's disease; Phosphorylation

Indexed keywords

8 (3 CHLOROSTYRYL)CAFFEINE; ADENOSINE A2A RECEPTOR; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDOPAMINE; PHOSPHOPROTEIN DARPP 32; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; MOTOR CONTROL; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; ROTATION; SHAM PROCEDURE; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANTIPARKINSON AGENTS; CAFFEINE; CORPUS STRIATUM; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; LEVODOPA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOTOR ACTIVITY; MOVEMENT; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; SIGNAL TRANSDUCTION; UP-REGULATION;

RATTUS;

EID: 67349087704     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.04.028     Document Type: Article

References (41)

1. Arslan G., and Fredholm B.B. Stimulatory and inhibitory effects of adenosine A(2A) receptors on nerve growth factor-induced phosphorylation of extracellular regulated kinases 1/2 in PC12 cells. Neurosci. Lett. 292 (2000) 183-186
2. Aubert I., Guiqoni C., Håkansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., and Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57 (2005) 17-26
3. Berhow M.T., Hiroi N., and Nestler E.J. Regulation of ERK (extracellular signal regulated kinase), part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic exposure to morphine or cocaine. J. Neurosci. 16 (1996) 4707-4715
4. Bibb J.A., Snyder G.L., Nishi A., Yan Z., Meijer L., Fienberg A.A., Tsai L.H., Kwon Y.T., Girault J.A., Czernik A.J., Huganir R.L., Hemmings Jr. H.C., Nairn A.C., and Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402 (1999) 669-671
5. Bove J., Marin C., Bonastre M., and Tolosa E. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 46 (2002) 251-257
6. Brown A.M., Deutch A.Y., and Colbran R.J. Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur. J. Neurosci. 22 (2005) 247-256
7. Deak M., Clifton A.D., Lucocq L.M., and Alessi D.R. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. Embo J. 17 (1998) 4426-4441
8. Dunn K.L., Espino P.S., Drobic B., He S., and Davie J.R. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem. Cell. Biol. 83 (2005) 1-14
9. 2A adenosine receptors. J. Neurosci. 22 (2002) 1054-1062
10. Ferre S., Ciruela F., Canals M., Marcellino D., Burgueno J., Casadó V., Hillion J., Torvinen M., Fanelli F., Benedetti P.d.P., Goldberg S.R., Bouvier M., Fuxe K., Agnati L.F., Lluis C., Franco R., and Woods A. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10 (2004) 265-271
11. Fredholm B.B. Activation of adenylate cyclase from rat striatum and tuberculum olfactorium by adenosine. Med. Biol. 55 (1997) 262-267
12. Fukunaga K., Muller D., Ohmitsu M., Bakó E., DePaoli-Roach A.A., and Miyamoto E. Decreased protein phosphatase 2A activity in hippocampal long-term potentiation. J. Neurochem. 74 (2000) 807-817
13. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
14. Greengard P., Allen P.B., and Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23 (1999) 435-447
15. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioral responses to following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151 (1998) 334-342
16. Hauser R.A., Hubble J.P., and Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
17. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat. Disord. 9 (2003) 131-137
18. 2A antagonist KW-6002 with or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162 (2000) 321-327
19. Keyse S.M. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12 (2000) 186-192
20. Kostic S., Svetel M., Sternic N., Dragasevic N., and Przedborski S. Theophylline increases "on" time in advanced parkinsonian patients. Neurology 52 (1999) 1916
21. Kull B., Svenningsson P., and Fredholm B.B. Adenosine A(2A) receptors are colocalized with and activate G(olf) in rat striatum. Mol. Pharmacol. 58 (2000) 771-777
22. Lang A.E., and Obeso J.A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet. Neurology 3 (2004) 309-316
23. Lindskog M., Svenningsson P., Pozzi L., Kim Y., Fienberg A.A., Bibb J.A., Fredholm B.B., Nairn A.C., Greengard P., and Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418 (2002) 774-776
24. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80 (1995) 179-185
25. Nishi A., Bibb J.A., Snyder G.L., Higashi H., Nairn A.C., and Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12840-12845
26. Ouimet C.C., Langley-Gullion K.C., and Greengard P. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res. 808 (1998) 8-12
27. Oh J.D., and Chase T.N. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 23 (2002) 133-139
28. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates, 4th ed. (1998), Academic Press
29. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59 (2006) 64-74
30. Quiroz C., Gomes C., Pak A.C., Ribeiro J.A., Goldberg S.R., Hope B.T., and Ferre S. Blockade of adenosine A2A receptors prevents protein phosphorylation in the striatum induced by cortical stimulation. J. Neurosci. 26 (2006) 10808-10812
31. Rascol O., Sabatini U., Brefel C., Fabre N., Rai S., Senard J.M., Celsis P., Viallard G., Montastruc J.L., and Chollet F. Corticalmotor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 121 (1998) 527-533
32. 2A receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13 (1993) 1080-1087
33. 2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80 (1997) 1171-1185
34. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., Hervé D., Greengard P., and Fisone G. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 27 (2007) 6995-7005
35. 2A receptor signaling. Brain Res. 1129 (2007) 1-14
36. Tomiyama M., Kimura T., Maeda T., Tanaka H., Kannari K., and Baba M. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. Synapse 2 (2004) 218-222
37. Valjent E., Corvol J.C., Pages C., Besson M.J., Maldonado R., and Caboche J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J. Neurosci. 20 (2000) 8701-8709
38. Valjent E., Pages C., Herve D., Girault J.A., and Caboche J. Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur. J. Neurosci. 19 (2004) 1826-1836
39. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Hervé D., and Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 491-496
40. Wyatt A.W., Steinert J.R., Wheeler-Jones C.P., Morgan A.J., Sugden D., Pearson J.D., Sobrevia L., and Mann G.E. Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. Faseb J. 16 (2002) 1584-1594
41. Westin J.E., Vercammen L., Strome E.M., Konradi C., and Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 62 (2007) 800-810